Laura Merritt
Acute Care · Selma, CANPI 1881865152
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,211, more than ten times the $223 reported in 2021. Among acute care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $93.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$899
- Corcept Therapeutics$771
- Phathom Pharmaceuticals, Inc.$651
- Madrigal Pharmaceuticals$538
- AbbVie$375
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$371
- plus $3K from 21 others
What the payments were for
- Food & beverage$6,538100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $899 |
| Corcept Therapeutics | 12 | $771 |
| Phathom Pharmaceuticals, Inc. | 7 | $651 |
| Madrigal Pharmaceuticals | 4 | $538 |
| AbbVie | 3 | $375 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $371 |
| Intercept Pharmaceuticals, Inc. | 3 | $354 |
| Otsuka America Pharmaceutical, Inc. | 6 | $309 |
| Boehringer Ingelheim | 2 | $232 |
| Axsome Therapeutics, Inc. | 2 | $218 |
| Vertex | 3 | $151 |
| Abbott | 1 | $147 |
| Neurocrine Biosciences, Inc. | 1 | $140 |
| Astellas Pharma US Inc | 1 | $125 |
| Kowa Pharmaceuticals America, Inc. | 1 | $125 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Xeris Pharmaceuticals, Inc. | 1 | $125 |
| Ardelyx, Inc. | 1 | $123 |
| Johnson & Johnson | 1 | $123 |
| Ironwood Pharmaceuticals, Inc | 1 | $123 |
| Ipsen Biopharmaceuticals, Inc | 1 | $122 |
| Amgen | 1 | $119 |
| Lilly USA, LLC | 1 | $105 |
| AstraZeneca | 1 | $85 |
| Alnylam Pharmaceuticals Inc. | 1 | $42 |
| Exact Sciences | 1 | $24 |
| Viiv Healthcare Company | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,538 in reported general payments places this provider in the 95th percentile of 1,153 acute care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 13 | $11,836 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $286 |
| Oxcarbazepine | 12 | $276 |
| Levothyroxine Sodium | 12 | $195 |
| Omeprazole | 22 | $151 |
| Tizanidine Hcl | 12 | $92 |
| Amlodipine Besylate | 18 | $85 |
| Lisinopril | 15 | $78 |
| Azithromycin | 16 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $105 | $11,83613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,153 acute care providers in California.
Other acute care in Selma
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
- Sunita BoparaiLos Angeles$37K
- Sherona BauLos Angeles$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.